Cascadian Therapeutics (CASC) Reports Q1 Loss of $0.30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Cascadian Therapeutics (CASC) Reports Q1 Loss of $0.30

Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET

May 9, 2017 7:00 AM EDT

SEATTLE, May 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ: CASC), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2017.

In the first quarter, we continued to build a solid management team and the financial foundation that will help us execute our core objectives over the next several years, said Scott Myers, President and CEO of Cascadian Therapeutics. We are focused on enrolling HER2CLIMB, our pivotal study of tucatinib in combination for late-stage HER2-positive metastatic breast cancer for patients with and without brain metastases.... More